- Conference Call Scheduled for February 25, 2009, 5:00 p.m. U.S. ET - EXTON, Pa., Feb. 18 /PRNewswire-FirstCall/ -- Adolor Corporation (Nasdaq: ADLR) today announced that it will hold a conference call at 5:00 p.m.

Adolor Corporation (Nasdaq: ADLR) announced today that GlaxoSmithKline (GSK) has returned to Adolor worldwide rights related to Entereg(R) (alvimopan) for chronic opioid bowel dysfunction (OBD).

Adolor Corporation (Nasdaq:ADLR) today reported financial results for the three and six months ended June 30, 2008.

Adolor Corporation (NASDAQ:ADLR) announced today that over 500 hospitals have now enrolled in the Entereg Access Support & Education (E.A.S.E.(TM)) Program. The Company estimates that these hospitals perform approximately 20% of the annual bowel resection procedures in the United States. The E.A.S.E.

Adolor Corporation (Nasdaq: ADLR) today issued an update on the Entereg(R) (alvimopan) Program for chronic opioid bowel dysfunction (OBD), under development in collaboration with GlaxoSmithKline (NYSE: GSK). The U. S.